EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

Short Versus Long Maribavir Treatment Duration for Cytomegalovirus Infection in Solid Organ Transplant Recipients: A Real‐World Cohort Study

David Martínez-Simón, Ibai Los-Arcos iD, Clara Ribera, Marta Bodro iD, Angela González, David Campany iD, Juliana Esperalba, Pol Clèries-Rovira iD, Ariadna Padullés, Núria Sabé, Montse Tuset iD, Edoardo Melilli iD und 4 weitere

Journal of Medical Virology · 2026-11 · 98 (11)

DOI: 10.1002/jmv.71186 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 26.10.2026. Verfasst von David Martínez-Simón und 15 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Antiviral Agents, Benzimidazoles, Cytomegalovirus Infections, Dichlororibofuranosylbenzimidazole. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maribavir (MBV) is an oral antiviral approved for refractory or resistant CMV, with an 8‐week regimen used in the pivotal clinical trial. We compared outcomes of longer versus shorter MBV courses in solid organ transplant (SOT) recipients. We conducted a multicenter retrospective cohort study of all adult SOT recipients from three centers in Catalonia, Spain, treated with MBV through November 30, 2024. Patients were followed up for 3 months and categorized as receiving ≥ 42 days (long‐duration group, LDG) or < 42 days (short‐duration group, SDG). Primary outcomes were CMV clearance and recurrence. Sixty‐one SOT recipients received MBV (29 in LDG; 32 in SDG). Median treatment duration was 64 versus 24 days ( p < 0.001). LDG patients had higher baseline CMV load (15 000 vs. 2005 IU/mL, p = 0.001), more high‐risk transplants (lung transplant: 8 vs. 1; CMV D + /R– mismatch: 52% vs. 28%), and more refractory/resistant infection, while intolerance was more common in SDG. CMV clearance was similar between groups (59% in LDG vs. 62% in SDG, p = 0.481), though clearance occurred later in LDG (27 vs. 13 days, p = 0.009). Recurrence rates were comparable (35% vs. 38%, p = 0.966). Refractory/resistance vs intolerance as the indication for MBV was the only factor associated with recurrence (51.6% vs. 21.4%, p = 0.017). Adverse events were generally mild (mainly dysgeusia), but four patients discontinued therapy because of this. In this real‐world cohort of SOT recipients with refractory, resistant, or valganciclovir‐intolerant CMV infection, selected patients receiving shorter MBV courses achieved viral clearance and recurrence rates comparable to the standard regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBenzimidazolesCytomegalovirus InfectionsDichlororibofuranosylbenzimidazoleOrgan TransplantationRibonucleosidesTransplant RecipientsAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesCytomegalovirusRecurrenceRetrospective StudiesSpainTime FactorsTreatment OutcomeViral Load

Stichwörter der Autor:innen

antiviralkidney transplantlung transplantrefractoryresistance

Substanzen

Antiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazolemaribavirRibonucleosides

Autor:innen und Institutionen

  • Infectious Diseases Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Pharmacy Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
  • Infectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Nephrology and Kidney Transplantation Department, National Reference Center on Complex Glomerular Disease (CSUR), IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Pharmacy Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

ORCID-Profile: Ibai Los-Arcos, Marta Bodro, David Campany, Pol Clèries-Rovira, Montse Tuset, Edoardo Melilli, Víctor Monforte, Oscar Len

Zitieren

APA

Martínez-Simón, D., Los-Arcos, I., Ribera, C., Bodro, M., González, A., Campany, D., Esperalba, J., Clèries-Rovira, P., Padullés, A., Sabé, N., Tuset, M., Melilli, E., Bestard, O., Monforte, V., López-Veiga, A., & Len, O. (2026). Short Versus Long Maribavir Treatment Duration for Cytomegalovirus Infection in Solid Organ Transplant Recipients: A Real‐World Cohort Study. Journal of Medical Virology, 98(11). https://doi.org/10.1002/jmv.71186

Vancouver

Martínez-Simón D, Los-Arcos I, Ribera C, Bodro M, González A, Campany D, et al. Short Versus Long Maribavir Treatment Duration for Cytomegalovirus Infection in Solid Organ Transplant Recipients: A Real‐World Cohort Study. Journal of Medical Virology. 2026;98(11). doi:10.1002/jmv.71186

BibTeX
@article{MartnezSimn2026,
  author = {Martínez-Simón, David and Los-Arcos, Ibai and Ribera, Clara and Bodro, Marta and González, Angela and Campany, David and Esperalba, Juliana and Clèries-Rovira, Pol and Padullés, Ariadna and Sabé, Núria and Tuset, Montse and Melilli, Edoardo and Bestard, Oriol and Monforte, Víctor and López-Veiga, Alberto and Len, Oscar},
  title = {Short Versus Long Maribavir Treatment Duration for Cytomegalovirus Infection in Solid Organ Transplant Recipients: A Real‐World Cohort Study},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {11},
  doi = {10.1002/jmv.71186}
}
Kostenlos starten →